Research at Inova

INOVA® | Parkinson's and Movement Disorders Center

Speaker:
Dr. Drew Falconer

Medical Director,
Movement Disorders
Specialist
IPMDC

RESEARCH IS IMPORTANT

- Moving therapies forward.
- Altruism.
- More important now than ever.
- Components in person, virtual components as well
- Clean and safe

PARKINSON'S DISEASE - ORCHESTRA

- **ORCHESTRA**: Evaluates the safety and tolerability of oral UCB0599 in patients with early Parkinson's Disease
  - Potential to reduce disease progression in study participants with early PD
  - Time commitment: Approximately 12 - 27 months
  - To be eligible to participate:
    - Must be 40 – 80 years of age, with a diagnosis made by a neurologist within 2 years of first study visit.
    - Have a screening DaT-SPECT
    - Never taken medications for treatment of motor symptoms of PD

ESSENTIAL TREMOR – PRAX-944

- A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Range Finding Clinical Trial to Evaluate the Tolerability, Safety, and Efficacy of PRAX-944 in the Treatment of Adults with Essential Tremor
  - Time commitment: 14 – 16 weeks
  - To be eligible to participate:
    - Must be at least 18 years of age
    - Has a diagnosis of ET, including:
      - Tremor syndrome of bilateral upper limb action tremor
      - At least 3 years in duration
    - If currently receiving any medication for ET, is on a stable dose of any of these medications for ET for 1 month prior to Screening.
    - If receiving primidone for ET, is willing and able to discontinue.

ESSENTIAL TREMOR – SAGE-324

- A Phase 2 Double-blind, Randomized, Placebo-Controlled, Dose-Response Study of SAGE-324 for the Treatment of Essential Tremor
  - Time commitment: Approximately 19 weeks
  - To be eligible to participate:
    - Must be 18 – 80 years of age
    - Has a diagnosis of ET - at 3 years in duration
    - Has not received botulinum toxin for treatment of upper limb tremor within 6 months of screening.

PARKINSONISM – MSA - AMULET

- Interventional, randomized, double-blind, parallel-group, placebo-controlled, multi-centre study to assess the efficacy, safety and tolerability of Lu AF82422 in patients with Multiple System Atrophy.
  - Time commitment: 70 – 94 weeks
  - To be eligible to participate:
    - Must be 40 – 75 years of age
    - Diagnosis of possible or probable MSA of the parkinsonian sub-type (MSA-P) or cerebellar sub-type (MSA-C)
    - Less than 5 years from the time of onset of motor and/or autonomic (orthostatic or urinary) MSA symptoms
    - Has a knowledgeable and reliable caregiver who will be available throughout the study
    - Does not have 2 or more blood relatives with a history of MSA
    - Has not been treated with an active vaccine targeting α-synuclein

ALZHEIMER'S DEMENTIA – ICARE AD

- International Collaboration for Real-World Evidence in Alzheimer's Disease (ICARE AD) - A Prospective Real-World Observational Study of Aducanumab in Patients with Alzheimer's Disease in the US

- Time commitment: Approximately 5 years
- To be eligible to participate:
  - Must be at least 18 years of age
  - Must be eligible to receive treatment with aducanumab
  - Willing and able to complete patient reported outcome surveys
  - Has an informant/care partner, who is able to provide accurate information about the patient's cognitive and functional abilities
  - Must be willing to provide blood samples
  - May not be enrolled in any interventional clinical study

ALZHEIMER'S DISEASE - ASPECT

- Evaluates the safety and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) for the treatment of agitation in patients with dementia of the Alzheimer's type
  - Time commitment = Approximately 5 months
  - To be eligible to participate:
    - Must be 50 – 90 years of age
    - With moderate-to-sever agitation that interferes with daily routine for at least 2 weeks prior to 1st study visit
    - Require pharmacotherapy for the treatment of agitation
    - Must have a reliable caregiver who is able and willing to comply with all study procedures, including adherence to administering study drug and not administering any prohibited medications during the course of the study, and who spends a minimum of 2 hours per day for 4 days per week with the patient.

ALZHEIMER'S DISEASE – NEW IDEAS

- Evaluate the utility of beta-amyloid PET to exclude Alzheimer's disease in a diverse population of Medicare beneficiaries with cognitive impairment
  - Time commitment: 90 days
  - To be eligible to participate:
    - Medicare beneficiary with Medicare as primary insurance
    - Meet criteria for Mild Cognitive Impairment or Dementia
    - Bran MRI and/or CT within 24 months prior to enrollment
    - Clinical laboratory assessment within 12 months prior to enrollment

STAY TUNED

- In talks for 4 other studies on therapies.
- Follow our newsletter and Facebook for updates.

THANK YOU!

INOVA® | Parkinson's and Movement Disorders Center

Find us on Facebook!

Join our newsletter!
http://eepurl.com/gPkGlf

Stay up to date on all
of our center's offerings!

Sonia.Gow@inova.org
703-375-9987

www.inova.org/move